Arcturus Therapeutics reports Q3 2026 results and outlines late‑2026/2027 pipeline milestones
Arcturus Therapeutics announced third‑quarter 2026 financials, posting revenue of $18.3 million and a net loss of $7.4 million. The company said cash and cash equivalents stood at $184.8 million, giving it a runway of more than two years into 2028. It also detailed upcoming clinical milestones: ARCT‑032 cystic fibrosis Phase 2 enrollment is expected to finish by year‑end 2026 with data slated for Q2 2027, and ARCT‑2601 for OTC deficiency will begin Phase 2 dosing in Q1 2027 with top‑line results anticipated in the second half of 2027. The new LUNAR 2.0 delivery platform showed a 38‑fold potency gain in non‑human primate studies.
Why it matters
The cash runway assures investors the company can fund its late‑2026 and 2027 milestones without immediate financing. Successful Phase 2 data for ARCT‑032 or ARCT‑2601 could significantly de‑risk the pipeline and drive future revenue growth, according to the company’s statements.
Key facts
- 1Q3 2026 revenue was $18.3 million. tradingview.com
- 2Net loss for the quarter was $7.4 million. finance.yahoo.com
- 3Cash and cash equivalents were $184.8 million as of September 30 2026. sec.gov
- 4ARCT‑032 Phase 2 enrollment is expected to be completed by year‑end 2026. stocktitan.net
- 5ARCT‑2601 Phase 2 dosing is planned for Q1 2027 with top‑line data expected in H2 2027. stocktitan.net
- 6LUNAR 2.0 demonstrated a 38‑fold potency improvement over the key lipid in ARCT‑810 in non‑human primate studies. stocktitan.net
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.